Open an account

Altimmune

ALT · NASDAQ

$2.30+$0.07 (+3.14%)TodayMarket closed ·
Prev close $2.23

About ALT

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 57 full-time employees. The company went IPO on 2005-10-06. The firm is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. The company has completed phase II development of pemvidutide. The company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.

Employees
57
Headquarters
Gaithersburg, Maryland
Listed
Oct 6, 2005
Sector
Health Care
Industry
Biotechnology
Website
altimmune.com

ALT key statistics

Market cap
447.39M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.89M
Volume
2.31M
Open price
$2.22
High today
$2.32
Low today
$2.20
52 Week high
$6.44
52 Week low
$2.17

Altimmune (ALT) at a glance

Altimmune (ALT) last traded at $2.30, with a market cap of 447.39M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.20 and $2.32. The current price is 4.5% above the day's low and 0.9% below its high.

Volume so far is 2.31M shares, below the average of 3.89M shares a day.

Over the past year Altimmune has ranged from $2.17 to $6.44, and now sits 3% of the way up that range.

Altimmune met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.12 per share against an estimate of -$0.1399.

The average analyst price target is $17.45, 658.8% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $17.45
Low
$11.11
Now
$2.30
High
$29.40

ALT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 17.8% on average.

  1. Q3 FY24: reported -$0.32 per share against an estimate of -$0.3574
  2. Q4 FY24: reported -$0.33 per share against an estimate of -$0.3307
  3. Q1 FY25: reported -$0.26 per share against an estimate of -$0.3668
  4. Q2 FY25: reported -$0.27 per share against an estimate of -$0.3262
  5. Q3 FY25: reported -$0.21 per share against an estimate of -$0.2843
  6. Q4 FY25: reported -$0.27 per share against an estimate of -$0.2451
  7. Q1 FY26: reported -$0.18 per share against an estimate of -$0.2478
  8. Q2 FY26: reported -$0.12 per share against an estimate of -$0.1399

ALT news

  • 9 Health Care Stocks Whale Activity In Today’s Session

  • Press releaseGlobe Newswire

    Altimmune Announces Second Quarter 2026 Financial Results and Business Update

  • Vandana Singh

    Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Press releaseGlobe Newswire

    Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

  • Press releaseGlobe Newswire

    Altimmune Announces First Quarter 2026 Financial Results and Business Update

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Press releasePRNewswire

    Anti-Aging Protein Research Takes a Step Forward with Cell Cloning

Similar companies

Companies in the same industry as Altimmune

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.